What is SeaStar Medical Holding Cash-to-Debt?
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. SeaStar Medical Holding's cash to debt ratio for the quarter that ended in Dec. 2023 was 0.02.
If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, SeaStar Medical Holding couldn't pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.
The historical rank and industry rank for SeaStar Medical Holding's Cash-to-Debt or its related term are showing as below:
ICU'
s Cash-to-Debt Range Over the Past 10 Years
Min: 0.01 Med: 0.11 Max: 33.82
Current: 0.02
During the past 4 years, SeaStar Medical Holding's highest Cash to Debt Ratio was 33.82. The lowest was 0.01. And the median was 0.11.
SeaStar Medical Holding Cash-to-Debt Historical Data
The historical data trend for SeaStar Medical Holding's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
SeaStar Medical Holding Cash-to-Debt Chart
|
SeaStar Medical Holding Annual Data
|
|
Trend |
Dec20 |
Dec21 |
Dec22 |
Dec23 |
| Cash-to-Debt |
|
33.82 |
0.20 |
0.01 |
0.02 |
|
SeaStar Medical Holding Quarterly Data
|
|
Dec20 |
Mar21 |
Jun21 |
Dec21 |
Mar22 |
Jun22 |
Sep22 |
Dec22 |
Mar23 |
Jun23 |
Sep23 |
Dec23 |
| Cash-to-Debt |
Get a 7-Day Free Trial
|
|
|
|
|
0.01 |
0.08 |
- |
0.01 |
0.02 |
Competitive Comparison of SeaStar Medical Holding's Cash-to-Debt
For the Biotechnology subindustry, SeaStar Medical Holding's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
SeaStar Medical Holding's Cash-to-Debt Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, SeaStar Medical Holding's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where SeaStar Medical Holding's Cash-to-Debt falls into.
SeaStar Medical Holding Cash-to-Debt Calculation
This is the ratio of a company's
Cash, Cash Equivalents, Marketable Securities
to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.
SeaStar Medical Holding's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:
SeaStar Medical Holding's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SeaStar Medical Holding (SeaStar Medical Holding) Business Description
Traded in Other Exchanges
N/A
Address
3513 Brighton Boulevard, Suite 410, Denver, CO, USA, 80216
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses.
Executives
| Heel Kenneth Van |
director |
C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121 |
| Kevin Chung |
officer: Chief Medical Officer |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Richard D. Russell |
director |
3201 W BAY VISTA AVE, TAMPA FL 33611 |
| Bruce M. Rodgers |
director |
302 KNIGHTS RUN AVE., STE. 1000, TAMPA FL 33602 |
| Andres Lobo |
director |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Caryl Baron |
officer: See Remarks |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Eric Schlorff |
director, officer: Chief Executive Officer |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Rick Barnett |
director |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Allan Collins |
director |
C/O SEASTAR MEDICAL, INC., 3513 BRIGHTON BOULEVARD, SUITE 410, DENVER CO 80216 |
| Dow Employees' Pension Plan Trust |
10 percent owner |
2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674 |
| Union Carbide Employees' Pension Plan Trust |
10 percent owner |
2211 H.H. DOW WAY, SSC BUILDING, MIDLAND MI 48674 |
| Martin A Traber |
director |
100 N TAMPA STREET, SUITE 2700, TAMPA FL 33602 |
| Lm Funding America, Inc. |
10 percent owner |
1200 WEST PLATT STREET, SUITE 100, TAMPA FL 33606 |
| Craig E Burson |
director |
400 N. PARK AVENUE, UNIT 10B, BRECKENRIDGE CO 80424 |
| Bruce H Bennett |
director |
3929 ARLINGTON DRIVE, PALM HARBOR FL 34685 |
SeaStar Medical Holding (SeaStar Medical Holding) Headlines
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ICU has been successfully added to your